Vistagen Reports Fiscal 2024 Third Quarter Financial Results and Provides Corporate UpdateBusiness Wire • 02/13/24
Vistagen to Report Fiscal Year 2024 Third Quarter Financial Results and Host Corporate Update Conference Call on February 13, 2024Business Wire • 02/06/24
Vistagen Receives Notice from European Patent Office of Intention to Grant Patent for AV-101 to Treat Neuropathic PainBusiness Wire • 12/27/23
Vistagen Provides Corporate Update and Reports Fiscal 2024 Second Quarter Financial ResultsBusiness Wire • 11/09/23
Vistagen to Present Positive Fasedienol Phase 3 Data and Positive PH80 Phase 2A Data at Upcoming Scientific ConferencesBusiness Wire • 11/07/23
Vistagen To Report Second Quarter Financial Results and Host Corporate Update Conference Call on November 9, 2023Business Wire • 11/06/23
Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH80 for Acute Management of the Symptoms of Premenstrual Dysphoric DisorderBusiness Wire • 09/12/23
Vistagen and Fuji Enter Exclusive Negotiation Agreement for a Potential License to Develop and Commercialize Vistagen's Investigational Menopausal Hot Flash Therapy, PH80 Nasal Spray, in JapanBusiness Wire • 09/05/23
Subsequent to the Release of Positive Phase 3 Trial Results, Vistagen Provides Corporate Update and Reports Fiscal 2024 First Quarter Financial ResultsBusiness Wire • 08/10/23